FDA approves Tezspire, first drug targeting TSLP, for chronic sinusitis with nasal polyps in patients 12 and older.

The FDA has approved Tezspire, a biologic drug by Amgen and AstraZeneca, for treating chronic rhinosinusitis with nasal polyps in patients aged 12 and older. It is the first approved therapy targeting thymic stromal lymphopoietin for this condition. Based on the phase 3 Waypoint trial, Tezspire significantly reduced nasal polyp severity and cut surgery and steroid use by 92% compared to placebo. The drug is approved as an add-on maintenance treatment for inadequately controlled disease. Regulatory reviews are ongoing in Europe, China, and Japan.